Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma

BACKGROUND: Anti-programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) immunotherapy has been proved to be effective on gastric cancer in ongoing clinical trials. However, the value of PD-L1 in predicting responses of patients with gastric cancer to anti-PD-1/PD-L1 immunotherapy is controversial...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Yuan, Li, Su, Xu, Dazhi, Chen, Shangxiang, Cai, Yuchen, Jiang, Wenqi, Zhang, Xinke, Sun, Jin, Wang, Kefeng, Chang, Boyang, Wang, Fenghua, Hong, Minghuang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5534127/
https://www.ncbi.nlm.nih.gov/pubmed/28754154
http://dx.doi.org/10.1186/s40880-017-0226-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5534127/
https://www.ncbi.nlm.nih.gov/pubmed/28754154
http://dx.doi.org/10.1186/s40880-017-0226-3

Ejemplares similares